Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Cancer·2019

Same author

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Blood cancer journal·2019

Same author

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Nature communications·2019

Same author

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia·2019

Same author

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Journal of hematology & oncology·2019

Same author

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

The Lancet. Haematology·2018

Search research articles

Related Experiment Video

Updated: Mar 29, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Chemoimmunotherapy for hairy cell leukemia.

Farhad Ravandi¹

¹Department of Leukemia, The University of Texas, MD Anderson Cancer Center, USA.

Best Practice & Research. Clinical Haematology

|November 29, 2015

Summary

This summary is machine-generated.

Nucleoside analogs like cladribine are effective for hairy cell leukemia (HCL), but relapses occur. Chemo-immunotherapy combining these drugs with monoclonal antibodies like rituximab shows promise for durable HCL treatment.

Keywords:

Chemoimmunotherapy Hairy cell leukemia Nucleoside analogs Rituximab

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Mar 29, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Hematology
Oncology
Immunology

Background:

Hairy cell leukemia (HCL) treatment has advanced significantly due to nucleoside analogs (cladribine, pentostatin).
Despite high efficacy, relapse-free survival curves for HCL indicate that many patients eventually relapse.
Understanding HCL pathogenesis has yielded novel relapse treatment options, but long-term durability remains uncertain.

Purpose of the Study:

To review the efficacy of current HCL treatments.
To explore novel therapeutic strategies for relapsed HCL.
To evaluate the potential of chemo-immunotherapy for HCL.

Main Methods:

Literature review of nucleoside analog efficacy in HCL.
Analysis of studies investigating novel treatments for relapsed HCL.
Assessment of combination chemo-immunotherapy regimens, including rituximab.

Main Results:

Nucleoside analogs demonstrate high efficacy but do not prevent all relapses.
Novel agents offer effective options for relapsed HCL, though long-term outcomes are pending.
Combination chemo-immunotherapy with nucleoside analogs and rituximab is safe and effective.

Conclusions:

Chemo-immunotherapy, particularly with rituximab, may become a preferred frontline strategy for HCL.
Further investigation into chemo-immunotherapy approaches is warranted.
Socioeconomic factors and other monoclonal antibodies should be considered for future HCL treatment strategies.